This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shattuck, D. L.
Right arrow Articles by Sweeney, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shattuck, D. L.
Right arrow Articles by Sweeney, C.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, March 2007, p. 1934-1946, Vol. 27, No. 5
0270-7306/07/$08.00+0     doi:10.1128/MCB.00757-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy{triangledown}

David L. Shattuck,{dagger} Jamie K. Miller,{dagger} Melanie Laederich,{ddagger} Melanie Funes, Heidi Petersen, Kermit L. Carraway III, and Colleen Sweeney*

UC Davis Cancer Center, Sacramento, California 95817

Received 1 May 2006/ Returned for modification 16 June 2006/ Accepted 8 December 2006

The Met receptor tyrosine kinase regulates a complex array of cellular behaviors collectively known as "invasive growth." While essential for normal development and wound repair, this program is frequently co-opted by tumors to promote their own growth, motility, and invasion. Met is overexpressed in a variety of human tumors, and this aberrant expression correlates with poor patient prognosis. Previous studies indicate that Met receptor levels are governed in part by cbl-mediated ubiquitination and degradation, and uncoupling of Met from cbl-mediated ubiquitination promotes its transforming activity. Here we describe a novel mechanism for Met degradation. We find that the Met receptor interacts with the transmembrane protein LRIG1 independent of hepatocyte growth factor (HGF) stimulation and that LRIG1 destabilizes the Met receptor in a cbl-independent manner. Overexpression of LRIG1 destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to HGF. LRIG1 knockdown increases Met receptor half-life, indicating that it plays an essential role in Met degradation. Finally, LRIG1 opposes Met synergy with the ErbB2/Her2 receptor tyrosine kinase in driving cellular invasion. We conclude that LRIG1 is a novel suppressor of Met function, serving to regulate cellular receptor levels by promoting Met degradation in a ligand- and cbl-independent manner.

* Corresponding author. Mailing address: UC Davis Cancer Center, Research Building III, Room 1400, 4645 2nd Ave., Sacramento, CA 95817. Phone: (916) 734-0726. Fax: (916) 734-0190. E-mail: casweeney{at}ucdavis.edu.

{triangledown} Published ahead of print on 18 December 2006.

{dagger} D.L.S. and J.K.M. contributed equally to this work.

{ddagger} Present address: Oregon Health Sciences University, Portland, OR 97239.

Molecular and Cellular Biology, March 2007, p. 1934-1946, Vol. 27, No. 5
0270-7306/07/$08.00+0     doi:10.1128/MCB.00757-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Peterfi, Z., Donko, A., Orient, A., Sum, A., Prokai, A., Molnar, B., Vereb, Z., Rajnavolgyi, E., Kovacs, K. J., Muller, V., Szabo, A. J., Geiszt, M. (2009). Peroxidasin Is Secreted and Incorporated into the Extracellular Matrix of Myofibroblasts and Fibrotic Kidney. Am. J. Pathol. 175: 725-735 [Abstract] [Full Text]  
  • Abraira, V. E., del Rio, T., Tucker, A. F., Slonimsky, J., Keirnes, H. L., Goodrich, L. V. (2008). Cross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear. Development 135: 4091-4099 [Abstract] [Full Text]  
  • Miller, J. K., Shattuck, D. L., Ingalla, E. Q., Yen, L., Borowsky, A. D., Young, L. J.T., Cardiff, R. D., Carraway, K. L. III, Sweeney, C. (2008). Suppression of the Negative Regulator LRIG1 Contributes to ErbB2 Overexpression in Breast Cancer. Cancer Res. 68: 8286-8294 [Abstract] [Full Text]  
  • Goldoni, S., Seidler, D. G., Heath, J., Fassan, M., Baffa, R., Thakur, M. L., Owens, R. T., McQuillan, D. J., Iozzo, R. V. (2008). An Antimetastatic Role for Decorin in Breast Cancer. Am. J. Pathol. 173: 844-855 [Abstract] [Full Text]  
  • Zhao, H., Tanegashima, K., Ro, H., Dawid, I. B. (2008). Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways. Development 135: 1283-1293 [Abstract] [Full Text]  
  • Shattuck, D. L., Miller, J. K., Carraway, K. L. III, Sweeney, C. (2008). Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells. Cancer Res. 68: 1471-1477 [Abstract] [Full Text]  
  • Ledda, F., Bieraugel, O., Fard, S. S., Vilar, M., Paratcha, G. (2008). Lrig1 Is an Endogenous Inhibitor of Ret Receptor Tyrosine Kinase Activation, Downstream Signaling, and Biological Responses to GDNF. J. Neurosci. 28: 39-49 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»